Realtime | Geld | Brief | Zeit |
---|---|---|---|
5,100 | 5,250 | 23:00 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME | - | HKEx | ||
27.03. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
27.03. | Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan | 5 | Benzinga.com | ||
27.03. | Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - Should You Sell? | 2 | MarketBeat | ||
ASCENTAGE PHARMA GROUP Aktie jetzt für 0€ handeln | |||||
27.03. | Ascentage Pharma Group International GAAP EPS of -$0.18, revenue of $134.3M | 1 | Seeking Alpha | ||
27.03. | ASCENTAGE-B (06855): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024 | 1 | HKEx | ||
27.03. | JPMorgan sets Ascentage Pharma stock to Overweight, $27 target | 4 | Investing.com | ||
26.03. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA TO PRESENT FIVE PRECLINICAL STUDIES FROM INNOVATIVE PIPELINE AT AMERICAN ASSOCIATION OF ... | 1 | HKEx | ||
26.03. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025 | 2 | GlobeNewswire (USA) | ||
13.03. | ASCENTAGE-B (06855): NOTICE OF BOARD MEETING | - | HKEx | ||
12.03. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
12.03. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025 | 1 | GlobeNewswire (USA) | ||
06.03. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - OLVEREMBATINIB GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR THE TREATMENT OF PHILADELPHIA CHROMOSOME-POSITIVE ... | 1 | HKEx | ||
06.03. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) | 64 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, March 05, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing... ► Artikel lesen | |
25.02. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
25.02. | ASCENTAGE-B (06855): CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE | - | HKEx | ||
13.02. | ASCENTAGE-B (06855): CLOSING OF THE PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION IN RELATION TO THE OFFERING OF AMERICAN DEPOSITARY SHARES | 1 | HKEx | ||
12.02. | ASCENTAGE-B (06855): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
11.02. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
07.02. | Ascentage Pharma announces underwriters partially exercise option to purchase additional ADS | 1 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 36,200 | -1,92 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen auf "Buy" mit einem Kursziel von 52 US-Dollar belassen. Analyst Tycho Peterson beschäftige sich in einer am Freitag... ► Artikel lesen | |
EVOTEC | 5,900 | -0,08 % | Kursraketen und Übernahmefantasie! Steyr Motors, Evotec und Defence Therapeutics! | Steyr Motors reitet jetzt nicht nur die Rüstungs-, sondern auch die Übernahmewelle. Nach der Kooperationsmeldung mit einer Rheinmetall-Tochter ist der Nischenwert zum Shootingstar geworden. Allerdings... ► Artikel lesen | |
TEMPUS AI | 46,220 | -7,36 % | Tempus AI, Inc. (NASDAQ:TEM) Sees Significant Increase in Short Interest | ||
BIONTECH | 83,65 | -1,82 % | Biontech-Partner unter Druck: Schwerer Vorwurf an Pfizer: War der Covid-Impfstoff viel früher ready? | © Foto: picture alliance/pressefoto_korb/Micha Korb - pressefoto_korb picture alliance/pressefoto_korb/Micha KorbIm Zentrum steht die Frage: Hat Pfizer die Bekanntgabe des Erfolgs seines gemeinsam mit... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 13,600 | -12,31 % | Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) | - Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM -- Four-week treatment with EDG-7500 demonstrated... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 43,110 | -7,36 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
BEAM THERAPEUTICS | 16,425 | -11,07 % | Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration | U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 28,120 | -5,48 % | Avidity Biosciences Inc Aktie: Neue Marktbedingungen, was bedeutet das? | Avidity Biosciences verzeichnete am Freitag einen Kursrückgang von 2,95 Prozent auf 31,60 USD. Trotz dieser kurzfristigen Schwäche konnte das Unternehmen im Monatsvergleich ein Plus von 7,67 Prozent... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 16,180 | -2,53 % | Arcutis Biotherapeutics, Inc.: Arcutis and Padagis Agree to Stay Patent Lawsuit | WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
OSR HOLDINGS | 2,430 | +65,31 % | OSR Holdings Inc.: OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate ... | SEOUL, South Korea, April 3, 2025 /PRNewswire/ -- OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies... ► Artikel lesen | |
BB BIOTECH | 30,450 | -2,87 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen | |
MODERNA | 23,365 | -8,59 % | Impfstoff-Aktien Moderna, BioNTech und Co massiv unter Druck - Gegenwind in den USA | Auch zum Start in die neue Handelswoche bahnen sich erneut Kursverluste bei einigen US-gelisteten Aktien aus dem Pharma- und Biotech-Sektor an. Vor allem bei den Impfstoff-Titeln geht es teilweise kräftig... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,800 | -9,09 % | Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March | ||
CG ONCOLOGY | 18,750 | -16,41 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
ADMA BIOLOGICS | 19,470 | -3,71 % | How IBD Stock Of The Day ADMA Biologics Shrugged Off Accounting Debacle For A Bullish Comeback |